Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Adolor join forces to develop pain compounds

Pfizer and Adolor join forces to develop pain compounds

7th December 2007

Pfizer and Adolor have announced a worldwide collaboration to develop and commercialise the compounds ADL5859 and ADL5747 for the treatment of pain.

The companies have confirmed the formation of a joint steering committee that will guide the development of the products with Pfizer responsible for securing regulatory approvals and commercialisation on a global basis.

Under the agreement, Pfizer and Adolor will share revenues and expenses according to a 60/40 per cent distribution in the US.

Outside America, Pfizer will fund development activities and Adolor will receive royalties on Pfizer net sales as a result of commercialisation.

Dr Martin Mackay, president of Pfizer Global Research and Development, said that the collaboration highlighted the company’s commitment to its research and development goals.

He added: “Pfizer has a strong history in bringing to market novel pain solutions including Lyrica, Neurontin and Celebrex. However, there still remains a significant unmet medical need for patients suffering from a variety of debilitating pain conditions.”

Both compounds are proprietary Delta opoid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions.

Earlier this month, Pfizer announced that it had signed an agreement to acquire publicly-held biopharmaceutical firm Coley Pharmaceutical.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.